Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

详细信息    查看全文

• 作者：Michael E. Ernst ; PharmD^a ; ^b ; Barry R. Davis ; MD ; PhD^c ; ^{barry.r.davis@uth.tmc.edu} ; Elsayed Z. Soliman ; MD ; MSc ; MS^d ; Ronald J. Prineas ; MB ; BS ; PhD^d ; Peter M. Okin ; MD^e ; Alokananda Ghosh ; MD ; MS^c ; William C. Cushman ; MD^f ; Paula T. Einhorn ; MD ; MS^g ; Suzanne Oparil ; MD^h ; Richard H. Grimm Jr. ; MD ; PhDⁱ ; ^j ; ^k ; for the ALLHAT Collaborative Research Group¹
• 关键词：Amlodipine ; chlorthalidone ; electrocardiography ; lisinopril
• 刊名：Journal of the American Society of Hypertension
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：10
• 期：12
• 页码：930-938.e9
• 全文大小：325 K
• 卷排序：10

文摘

The comparative effects of chlorthalidone and other antihypertensives on electrocardiography (ECG) left ventricular hypertrophy (LVH) are unknown. Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial data were analyzed to determine the changes in ECG LVH through 2 and 4 years of follow-up. Chlorthalidone led to similar overall change in ECG Cornell voltage as amlodipine and lisinopril. Chlorthalidone's benefit in Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial cannot be attributed to a greater reduction in ECG LVH.